Stockscreener 앱 받기
1.31
3.32%
-0.045
시간 외 거래:
1.36
0.05
+3.82%
Alx Oncology Holdings Inc 주식(ALXO)의 최신 뉴스
ALX Oncology Holdings Inc.(NasdaqGS: ALXO) added to S&P Global BMI Index - marketscreener.com
Alx Oncology Holdings Stock Price Forecast. Should You Buy ALXO? - StockInvest.us
ALX Oncology Holdings Inc Share PriceALXO, RNS News, Articles, Quotes, & Charts (NASDAQ:ALXO) - Proactive financial news
ALXO: Lead assets advance toward phase III, with strong biomarker focus and robust financial runway - TradingView
ALX Oncology at Cantor healthcare conference: biomarker push takes center stage - Investing.com Canada
ALX Oncology at Wells Fargo conference: two drugs near key tests - Investing.com Canada
ALXO Q2 2026 Earnings: Narrower-Than-Expected Loss of -$0.12 Per Share Reflects Cost DisciplineDownward Estimate Revision - dars.gov.et
ALX Oncology to Present at Upcoming Investor Conferences in September - GlobeNewswire
ALXO Q2 2026 Earnings: Narrower Quarterly Loss and EPS Beat Amid Pipeline FocusDividend Earnings Report - dars.gov.et
ALX (ALXO) Stock: Ends Up by 2.26% at $2.04 on the Day; Trading Range: the Near-Term Reference Band Stretches From $1.94 to $2.14 at the CloseMomentum Trade - vinanet.vn
ALX (ALXO) EPS and Revenue: EPS Beats Its Estimate in the Latest Session; Stock Move: Shares Close 0.96% Lower on the DayEarnings Preview - vinanet.vn
HC Wainwright Has Positive View of ALX Oncology Q3 Earnings - MarketBeat
ALX Oncology Holdings Inc (ALXO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares - Investing.com
Alx oncology CEO Jason Lettmann disposes of $4,303 in shares By Investing.com - Investing.com India
Alx Oncology SVP Shelly Wong sells $1,105 of company stock - Investing.com
ALX Oncology (NASDAQ: ALXO) CEO trims stake for taxes - Stock Titan
Piper Sandler Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALX Oncology (ALXO) SVP Finance sells shares for taxes - Stock Titan
ALXO Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 17.9% EPS SurpriseEPS Consistency Score - vinanet.vn
ALX Oncology (ALXO) Holds Near $1.96 as Biotech Stock Consolidates Below ResistanceSingle Stock ETF - dars.gov.et
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
TCG Crossover group (NASDAQ: ALXO) reports 4.2% ALX Oncology stake in 13G/A - Stock Titan
ALXO Q2 2026 Earnings: EPS Beat of 17.92% Lifts Shares 4.15%Downward Estimate Revision - Vinanet
Is ALX Oncology Holdings (ALXO) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
H.C. Wainwright Maintains ALX Oncology(ALXO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
ALXO Q2 2026 Earnings: EPS Beats by 17.92% on Narrower Loss, But Shares Slide 6.31%EPS Miss Report - dars.gov.et
ALX Oncology Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
ALX Oncology Holdings Inc expected to post a loss of 15 cents a shareEarnings Preview - TradingView
ALX Oncology (ALXO) Holds Steady at $2.10 as Shares Consolidate Near Key SupportSector Sentiment - careplusvn.com
ALX Oncology (NASDAQ:ALXO) Issues Earnings Results - MarketBeat
ALX Oncology Holdings Inc 2Q 2026: Net loss $17.97M, Diluted EPS $(0.13) — 10-Q Summary - TradingView
ALXO: Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028 - TradingView
Is ALX Oncology Holdings Inc (ALXO) Turning a Corner After Q2 Ea - GuruFocus
ALX Oncology Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Investing News Network
ALX Oncology Reports Q2 2026 Net Loss of $18 Million - Quiver Quantitative
ALX Oncology reports Q2 2026 net loss of $18.0M, $153.4M cash; advances evorpacept and ALX2004 - TradingView
ALXO: Reduced net loss, robust cash position, and advancing clinical milestones drive outlook - TradingView
Clinical pipeline accelerates as ALX Oncology posts Q2 results and updates on ALX2004 study - Traders Union
ALXO Q2'26 Earnings: EPS estimate is (0.14) USD - TradingView
ALX Oncology (ALXO) Projected to Post Earnings on Tuesday - MarketBeat
ALX Oncology Holdings (ALXO) Holds Steady Near $1.94 as Biotech Sector Watches Key LevelsUnusual Call Volume - dars.gov.et
ALX Oncology (ALXO) Holds Near $1.94 as Shares Dip 0.51%Risk Parity Rebalance - dars.gov.et
BlackRock, Inc. Expands Stake in ALX Oncology Holdings Inc (ALXO) with Strategic Share Purchase - GuruFocus
ALXO Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Redmile Group LLC Acquires 4,699,470 Shares of ALX Oncology Holdings Inc. $ALXO - MarketBeat
ALX Oncology Holdings Inc (ALXO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
ALX Oncology Holdings Inc. $ALXO Stock Position Boosted by venBio Partners LLC - MarketBeat
BlackRock (NYSE: BLK) reports 5.4% passive stake in ALX Oncology (ALXO) - Stock Titan
ALX Oncology Holdings Inc (ALXO) Cash Flow - TradingKey
2,866,256 Shares in ALX Oncology Holdings Inc. $ALXO Purchased by Orbimed Advisors LLC - MarketBeat
ALX Oncology Holdings Inc (ALXO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ALX Oncology Holdings Inc (ALXO) Valuation: PE, PB & Fair Value Analysis - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.030|Chg%:+0.010 - TradingKey
ALX Oncology Holdings Inc (ALXO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ALXO|ALX Oncology Holdings Inc|Price:2.020|Chg%:-0.010 - TradingKey
TradingKey - TradingKey
ALX Oncology Holdings Inc. Revenue Breakdown – NASDAQ:ALXO - TradingView
ALXO Q1 2026 Earnings: EPS Beat Driven by Lower Operating CostsEarnings Deceleration Risk - vinanet.vn
3.06%
2.55%
자본화:
|
볼륨(24시간):